Single variable domain antibodies against OX40L, constructs and therapeutic use

• US 8,962,807 B2
• Filed: 12/14/2010
• Issued: 02/24/2015
• Est. Priority Date: 12/14/2009
• Status: Active Grant

• Current Assignee: Ablynx NV (Sanofi )
• Original Assignee: Ablynx NV (Sanofi )
• Inventors: Verdonck, Frank, Cornelis, Sigrid, Staelens, Stephanie
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US13/515,876
• Publication Number:
  US 20130018175A1
• Time in Patent Office: 1,533 Days
• Field of Search: None
• US Class Current: 530/387.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: C07K 16/2875 against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 against NGF C07K16/22, against TNF C07K16/241
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/22 from camelids, e.g. camel, llama or dromedary
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/569 Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn'"'"'s disease, inflammatory bowel disease, and/or arthrosclerosis.

Claims

1. Immunoglobulin single variable domain that specifically binds to OX40L (SEQ ID NO:

175), in which CDR1 is SEQ ID NO;

133;

CDR2 is SEQ ID NO;

147;

CDR3 is SEQ ID NO;

161;

wherein the immunoglobulin single variable domain is a VH domain, a VHH, a partially humanized VHH or a fully humanized VHH.

2. Immunoglobulin single variable domain according to claim 1, that can specifically bind to OX40L (SEQ ID NO:

175),

with a dissociation constant (K_D) of 10<sup>−

5</sup> to 10<sup>−

12</sup> moles/liter or less,

with a rate of association (k_on-rate) of between 10² M<sup>−

1</sup> s<sup>−

1</sup> to about 10⁷ M<sup>−

1</sup>s<sup>−

1</sup>,

with a rate of dissociation (k_off rate) between 1 s<sup>−

1</sup> and 10⁷ M<sup>−

1</sup>s<sup>−

1</sup>,

with an affinity of less than 500 nM,

having an IC50 value in an Amplified Luminescent Proximity Homogeneous Assay with 0.12 nM hOX40L and 0.2 nM OX40/Fc of less than 10 nM,

having an IC50 value in the FACS assay of less than 100 nM, and/or

having an IC50 value in the T-cell activation assay using human donors that is less than the IC50 of the benchmark Fab (SEQ ID NO;

177 and 178, representing the polypeptides of the heavy and light chain, respectively).

3. Immunoglobulin single variable domain according to claim 1, wherein said immunoglobulin single variable domain is chosen from the group consisting of

SEQ ID NO:

179;

SEQ ID NOs;

202 to 226;

immunoglobulin single variable domains that cross-block the binding to OX40L of at least one of SEQ ID NOs;

179 and 202 to 226, and

immunoglobulin single variable domains that are cross-blocked from binding to OX40L by at least one of SEQ ID NOs;

179 and 202 to 226.

4. Polypeptide that comprises or essentially consists of one or more immunoglobulin single variable domains according to claim 1.

5. Polypeptide according to claim 4, which further comprises one or more other residues or binding units, optionally linked via one or more peptidic linkers.

6. Polypeptide according to claim 5, in which said one or more other residues or binding units are chosen from the group consisting of immunoglobulin sequences, domain antibodies, and single domain antibodies.

7. Polypeptide according to claim 5, which is a multivalent construct, a multispecific construct, a multiparatopic construct, and/or has an increased half-life, compared to the corresponding immunoglobulin single variable domain.

8. Polypeptide according to claim 7, in which said one or more other binding units provide the polypeptide with increased half-life, compared to the corresponding immunoglobulin single variable domain.

9. Polypeptide according to claim 8, in which said one or more other binding units that provide the polypeptide with increased half-life are chosen from the group consisting of binding units that can bind to serum albumin, human serum albumin, a serum immunoglobulin, IgG, domain antibodies, single domain antibodies, single domain antibodies that can bind to serum albumin, and single domain antibodies that can bind to human serum albumin.

10. Polypeptide according to claim 4 that is chosen from the group consisting of SEQ ID NOs:

190, 231 and 232.

11. Nucleic acid or nucleotide sequence, that encodes an immunoglobulin single variable domain according to claim 1.

12. Non-human or isolated host cell that expresses, or that under suitable circumstances is capable of expressing, an immunoglobulin single variable domain according to claim 1.

13. Composition comprising at least one immunoglobulin single variable domain according to claim 1.

14. Method for producing an immunoglobulin single variable domain according to claim 1, said method at least comprising the step of:

expressing, in a suitable host cell or host organism or in another suitable expression system, a nucleic acid or nucleotide sequence encoding the immunoglobulin single variable domain;

optionally followed by isolating and/or purifying the immunoglobulin single variable domain.

16. Composition according to claim 13, further comprising a carrier.

15. Method for screening polypeptides that specifically bind to OX40L that comprises at least the steps of:

a) providing a set, collection or library of nucleic acids encoding polypeptides;

b) screening said set, collection or library of nucleic acids for a nucleic acid that encodes a polypeptide-that can bind to and/or has affinity for OX40L and that cross blocks an immunoglobulin single variable domain comprising SEQ ID NO;

179, or a humanized and/or sequence optimized immunoglobulin single variable domain selected from one of SEQ ID NOs;

206 to 226, or a polypeptide or construct selected from one of SEQ ID NOs;

190, 231, and 232; and

c) isolating said nucleic acid, followed by expressing said polypeptide.

17. An immunoglobulin single variable domain that specifically binds to OX40L, which consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), wherein:

(a) CDR1 is SEQ ID NO;

133,

CDR2 is SEQ ID NO;

147, and

CDR3 is SEQ ID NO;

161;

or

(b) CDR1 has 3, 2, or 1 amino acid difference with SEQ ID NO;

133 and

CDR2 has 3, 2, or 1 amino acid difference with SEQ ID NO;

147, and

CDR3 is SEQ ID NO;

161;

wherein the immunoglobulin single variable domain is a VH domain, a VHH, a partially humanized VHH or a fully humanized VHH.

18. An immunoglobulin single variable domain, which consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which

CDR1 has 3, 2, or 1 amino acid difference with SEQ ID NO:

133,

CDR2 is SEQ ID NO;

147, and

CDR3 is SEQ ID NO;

161;

wherein the immunoglobulin single variable domain is a VH domain, a VHH, a partially humanized VHH or a fully humanized VHH.

19. An immunoglobulin single variable domain, which consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which

CDR1 is SEQ ID NO:

133

CDR2 has 3, 2, or 1 amino acid difference with SEQ ID NO;

147, and

CDR3 is SEQ ID NO;

161;

wherein the immunoglobulin single variable domain is a VH domain, a VHH, a partially humanized VHH or a fully humanized VHH.

20. An immunoglobulin single variable domain, which consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which

CDR1 is SEQ ID NO:

133

CDR2 is SEQ ID NO;

147, and

CDR3 has 3, 2, or 1 amino acid difference with SEQ ID NO;

161;

wherein the immunoglobulin single variable domain is a VH domain, a VHH, a partially humanized VHH or a fully humanized VHH.